Europe Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.6% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of pancreatic cancer diagnostics market are:

Rise in prevalence and incidence of pancreatic cancer

Increase in awareness about the pancreatic cancer diagnostics

Market Players:

Some of the major players operating in the Europe pancreatic cancer diagnostics market are:

Canon Medical Systems ANZ Pty Limited.

Koninklijke Philips N.V.

Siemens Healthcare Private Limited

Grail

Myriad Genetics, Inc.

Abbott

Agilent Technologies, Inc.

Thermo Fisher Scientific

QIAGEN

MP BIOMEDICALS

Laboratory Corporation of America Holdings

DiaSource

Creative Biolabs

Meridian Life Science, Inc.

1 INTRODUCTION 91

1.1 OBJECTIVES OF THE STUDY 91
1.2 MARKET DEFINITION 91
1.3 OVERVIEW OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 91
1.4 CURRENCY AND PRICING 94
1.5 LIMITATIONS 94
1.6 MARKETS COVERED 94

2 MARKET SEGMENTATION 98

2.1 MARKETS COVERED 98
2.2 GEOGRAPHICAL SCOPE 99
2.3 YEARS CONSIDERED FOR THE STUDY 100
2.4 DBMR TRIPOD DATA VALIDATION MODEL 101
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 104
2.6 MULTIVARIATE MODELLING 105
2.7 MARKET END USER COVERAGE GRID 106
2.8 PRODUCT LIFELINE CURVE 107
2.9 DBMR MARKET POSITION GRID 108
2.10 VENDOR SHARE ANALYSIS 109
2.11 SECONDARY SOURCES 110
2.12 ASSUMPTIONS 110

3 EXECUTIVE SUMMARY 111

4 PREMIUM INSIGHTS 114

4.1 PESTEL ANALYSIS 115
4.2 PORTER'S FIVE FORCES MODEL 116

5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 117

6 EPIDEMIOLOGY 119

7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 120

8 MARKET OVERVIEW 123

8.1 DRIVERS 125
- 8.1.1 GROW IN PREVALENCE OF PANCREATIC CANCER 125
- 8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 125
- 8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 126
- 8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 126
8.2 RESTRAINTS 127
- 8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 127
- 8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 127
8.3 OPPORTUNITIES 128
- 8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 128
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 129
- 8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 129
8.4 CHALLENGES 130
- 8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 130
- 8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 130

9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131

9.1 OVERVIEW 132
9.2 IMAGING TEST 135
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 136
- 9.2.2 MAGNETIC RESONANCE IMAGING (MRI) 136
  - 9.2.2.1 MR CHOLANGIOPANCREATOGRAPHY 136
  - 9.2.2.2 MR ANGIOGRAPHY (MRA) 137
- 9.2.3 ULTRASOUND 137
  - 9.2.3.1 ABDOMINAL ULTRASOUND 137
  - 9.2.3.2 ENDOSCOPIC ULTRASOUND (EUS) 137
- 9.2.4 CHOLANGIOPANCREATOGRAPHY 137
  - 9.2.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 138
  - 9.2.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 138
  - 9.2.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 138
- 9.2.5 POSITRON EMISSION TOMOHRAPHY (PET) 138
- 9.2.6 OTHERS 138
9.3 BIOPSY 139
- 9.3.1 CT-GUIDED NEEDLE BIOPSY 140
- 9.3.2 FINE NEEDLE ASPIRATION (FNA) 140
- 9.3.3 CORE NEEDLE BIOPSY 140
- 9.3.4 OTHERS 140
9.4 BLOOD TEST 140
- 9.4.1 LIVER FUNCTION TEST 141
- 9.4.2 TUMOR MARKER 141
  - 9.4.2.1 CA 19-9 BIOMARKER TEST 142
  - 9.4.2.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 142
  - 9.4.2.3 CA 50 MARKER TEST 142
  - 9.4.2.4 OTHERS 142
- 9.4.3 OTHERS 142
9.5 GENOMIC TEST 143
9.6 OTHERS 144

10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 145

10.1 OVERVIEW 146
10.2 STAGE IV 149
10.3 STAGE III 149
10.4 STAGE II 150
- 10.4.1 STAGE IIA 151
- 10.4.2 STAGE IIB 151
10.5 STAGE I 151
- 10.5.1 STAGE IA 152
- 10.5.2 STAGE IB 152
10.6 STAGE 0 153

11 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 154

11.1 OVERVIEW 155
11.2 EXOCRINE TUMORS 158
- 11.2.1 INSTRUMENT-BASED PRODUCTS 159
- 11.2.2 PLATFORM-BASED PRODUCTS 159
- 11.2.3 KITS AND REAGENTS 159
- 11.2.4 OTHER CONSUMABLES 159
11.3 NEUROENDOCRINE TUMORS 159
- 11.3.1 INSTRUMENT-BASED PRODUCTS 160
- 11.3.2 PLATFORM-BASED PRODUCTS 160
- 11.3.3 KITS AND REAGENTS 161
- 11.3.4 OTHER CONSUMABLES 161

12 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 162

12.1 OVERVIEW 163
12.2 INSTRUMENT-BASED PRODUCTS 166
- 12.2.1 IMAGING 167
- 12.2.2 BIOPSY 167
12.3 PLATFORM-BASED PRODUCTS 167
- 12.3.1 NEXT-GENERATION SEQUENCING 168
- 12.3.2 MICROARRAYS 168
- 12.3.3 PCR 168
- 12.3.4 OTHERS 169
12.4 KITS AND REAGENTS 169
- 12.4.1 CA19-9 PANCREATIC CANCER TEST KITS 170
  - 12.4.1.1 ELISA TEST KITS 170
  - 12.4.1.2 CASETTE TEST KITS 170
  - 12.4.1.3 OTHERS 170
- 12.4.2 CEA PANCREATIC CANCER TEST KITS 171
  - 12.4.2.1 ELISA TEST KITS 171
  - 12.4.2.2 CASETTE TEST KITS 171
  - 12.4.2.3 OTHERS 171
12.5 OTHER CONSUMABLES 171

13 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 173

13.1 OVERVIEW 174
13.2 FLUORESCENT IN SITU HYBRIDIZATION 177
13.3 NEXT GENERATION SEQUENCING 178
13.4 FLUORIMMUNOASSAY 179
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 180
13.6 IMMUNOHISTOCHEMICAL 181
13.7 OTHERS 182

14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 183

14.1 OVERVIEW 184
14.2 SCREENING 187
- 14.2.1 INSTRUMENT-BASED PRODUCTS 188
- 14.2.2 PLATFORM-BASED PRODUCTS 188
- 14.2.3 KITS AND REAGENTS 188
- 14.2.4 OTHER CONSUMABLES 188
14.3 DIAGNOSTIC AND PREDICTIVE 188
- 14.3.1 INSTRUMENT-BASED PRODUCTS 189
- 14.3.2 PLATFORM-BASED PRODUCTS 189
- 14.3.3 KITS AND REAGENTS 189
- 14.3.4 OTHER CONSUMABLES 189
14.4 PROGNOSTIC 190
- 14.4.1 INSTRUMENT-BASED PRODUCTS 191
- 14.4.2 PLATFORM-BASED PRODUCTS 191
- 14.4.3 KITS AND REAGENTS 191
- 14.4.4 OTHER CONSUMABLES 191
14.5 RESEARCH 191
- 14.5.1 INSTRUMENT-BASED PRODUCTS 192
- 14.5.2 PLATFORM-BASED PRODUCTS 192
- 14.5.3 KITS AND REAGENTS 192
- 14.5.4 OTHER CONSUMABLES 192

15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 193

15.1 OVERVIEW 194
15.2 HOSPITALS 197
15.3 DIAGNOSTIC CENTERS 197
15.4 CANCER RESEARCH CENTERS 198
15.5 ACADEMIC INSTITUTES 199
15.6 AMBULATORY SURGICAL CENTERS 200
15.7 OTHERS 201

16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 202

16.1 OVERVIEW 203
16.2 DIRECT TENDER 206
16.3 RETAIL SALES 207
16.4 OTHERS 208

17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 209

17.1 EUROPE 210
- 17.1.1 GERMANY 225
- 17.1.2 FRANCE 234
- 17.1.3 UNITED KINGDOM 243
- 17.1.4 ITALY 252
- 17.1.5 SPAIN 261
- 17.1.6 RUSSIA 270
- 17.1.7 NETHERLANDS 279
- 17.1.8 POLAND 288
- 17.1.9 SWITZERLAND 297
- 17.1.10 BELGIUM 306
- 17.1.11 SWEDEN 315
- 17.1.12 NORWAY 324
- 17.1.13 DENMARK 333
- 17.1.14 FINLAND 342
- 17.1.15 TURKEY 351
- 17.1.16 REST OF EUROPE 360

18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 361

18.1 COMPANY SHARE ANALYSIS: EUROPE 361

19 SWOT ANALYSIS 362

20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 363

20.1 CANON MEDICAL SYSTEMS CORPORATION 363
- 20.1.1 COMPANY SNAPSHOT 363
- 20.1.2 REVENUE ANALYSIS 363
- 20.1.3 COMPANY SHARE ANALYSIS 364
- 20.1.4 PRODUCT PORTFOLIO 364
- 20.1.5 RECENT DEVELOPMENT 364
20.2 KONINKLIJKE PHILIPS N.V. 365
- 20.2.1 COMPANY SNAPSHOT 365
- 20.2.2 REVENUE ANALYSIS 365
- 20.2.3 COMPANY SHARE ANALYSIS 366
- 20.2.4 PRODUCT PORTFOLIO 366
- 20.2.5 RECENT DEVELOPMENTS 366
20.3 SIEMENS HEALTHCARE GMBH 368
- 20.3.1 COMPANY SNAPSHOT 368
- 20.3.2 REVENUE ANALYSIS 368
- 20.3.3 COMPANY SHARE ANALYSIS 369
- 20.3.4 PRODUCT PORTFOLIO 369
- 20.3.5 RECENT DEVELOPMENT 370
20.4 GRAIL 371
- 20.4.1 COMPANY PROFILE 371
- 20.4.2 COMPANY SHARE ANALYSIS 371
- 20.4.3 PRODUCT PORTFOLIO 372
- 20.4.4 RECENT DEVELOPMENT 372
20.5 MYRIAD GENETICS, INC. 373
- 20.5.1 COMPANY SNAPSHOT 373
- 20.5.2 REVENUE ANALYSIS 373
- 20.5.3 COMPANY SHARE ANALYSIS 374
- 20.5.4 PRODUCT PORTFOLIO 374
- 20.5.5 RECENT DEVELOPMENT 374
20.6 BD 375
- 20.6.1 COMPANY SNAPSHOT 375
- 20.6.2 REVENUE ANALYSIS 375
- 20.6.3 PRODUCT PORTFOLIO 376
- 20.6.4 RECENT DEVELOPMENT 376
20.7 BODITECH MED INC. 377
- 20.7.1 COMPANY PROFILE 377
- 20.7.2 PRODUCT PORTFOLIO 377
- 20.7.3 RECENT DEVELOPMENT 377
20.8 ABBOTT (2022) 378
- 20.8.1 COMPANY SNAPSHOT 378
- 20.8.2 REVENUE ANALYSIS 378
- 20.8.3 PRODUCT PORTFOLIO 379
- 20.8.4 RECENT DEVELOPMENT 379
20.9 FUJIFILM HOLDINGS AMERICA CORPORATION 380
- 20.9.1 COMPANY SNAPSHOT 380
- 20.9.2 REVENUE ANALYSIS 380
- 20.9.3 PRODUCT PORTFOLIO 381
- 20.9.4 RECENT DEVELOPMENT 381
20.10 ACCUBIOTECH CO., LTD. 382
- 20.10.1 COMPANY PROFILE 382
- 20.10.2 PRODUCT PORTFOLIO 382
- 20.10.3 RECENT DEVELOPMENTS 382
20.11 AGILENT TECHNOLOGIES, INC. 383
- 20.11.1 COMPANY PROFILE 383
- 20.11.2 REVENUE ANALYSIS 383
- 20.11.3 PRODUCT PORTFOLIO 384
- 20.11.4 RECENT DEVELOPMENT 384
20.12 CREATIVE BIOLABS. 385
- 20.12.1 COMPANY PROFILE 385
- 20.12.2 PRODUCT PORTFOLIO 385
- 20.12.3 RECENT DEVELOPMENT 385
20.13 CTK BIOTECH, INC. 386
- 20.13.1 COMPANY PROFILE 386
- 20.13.2 PRODUCT PORTFOLIO 386
- 20.13.3 RECENT DEVELOPMENT 386
20.14 DIASOURCE 387
- 20.14.1 COMPANY SNAPSHOT 387
- 20.14.2 PRODUCT PORTFOLIO 387
- 20.14.3 RECENT DEVELOPMENT 387

20.15 LABORATORY CORPORATION OF AMERICA HOLDINGS 388
- 20.15.1 COMPANY SNAPSHOT 388
- 20.15.2 REVENUE ANALYSIS 388
- 20.15.3 PRODUCT PORTFOLIO 389
- 20.15.4 RECENT DEVELOPMENTS 389
20.16 LEE BIOSCIENCE 390
- 20.16.1 COMPANY SNAPSHOT 390
- 20.16.2 PRODUCT PORTFOLIO 390
- 20.16.3 RECENT DEVELOPMENT 390
20.17 MERIDIAN BIOSCIENCE INC. 391
- 20.17.1 COMPANY PROFILE 391
- 20.17.2 PRODUCT PORTFOLIO 391
- 20.17.3 RECENT DEVELOPMENT 391
20.18 MP BIOMEDICALS. 392
- 20.18.1 COMPANY PROFILE 392
- 20.18.2 PRODUCT PORTFOLIO 392
- 20.18.3 RECENT DEVELOPMENTS 392
20.19 QIAGEN 393
- 20.19.1 COMPANY SNAPSHOT 393
- 20.19.2 REVENUE ANALYSIS 393
- 20.19.3 PRODUCT PORTFOLIO 394
- 20.19.4 RECENT DEVELOPMENT 394
20.20 SETIA SCIENTIFIC SOLUTION 395
- 20.20.1 COMPANY PROFILE 395
- 20.20.2 PRODUCT PORTFOLIO 395
- 20.20.3 RECENT DEVELOPMENTS 395
20.21 THERMO FISHER SCIENTIFIC INC. 396
- 20.21.1 COMPANY SNAPSHOT 396
- 20.21.2 REVENUE ANALYSIS 396
- 20.21.3 PRODUCT PORTFOLIO 397
- 20.21.4 RECENT DEVELOPMENT 397

21 QUESTIONNAIRE 398

22 RELATED REPORTS 402

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF PANCREATIC CANCER 80
TABLE 2 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 86
TABLE 3 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 4 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 88
TABLE 5 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 88
TABLE 6 EUROPE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 89
TABLE 7 EUROPE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 90
TABLE 8 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 9 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 92
TABLE 10 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 11 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 93
TABLE 12 EUROPE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 94
TABLE 13 EUROPE GENOMIC TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 14 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 100
TABLE 16 EUROPE STAGE IV IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 17 EUROPE STAGE III IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 18 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 19 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 103
TABLE 20 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 21 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 104
TABLE 22 EUROPE STAGE 0 IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 23 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 109
TABLE 24 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 25 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 111
TABLE 26 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 27 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 112
TABLE 28 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 117
TABLE 29 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
TABLE 30 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 119
TABLE 31 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 32 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 120
TABLE 33 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 34 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 122
TABLE 35 EUROPE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 122
TABLE 36 EUROPE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 123
TABLE 37 EUROPE OTHER CONSUMABLES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 38 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 128
TABLE 39 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
TABLE 40 EUROPE NEXT GENERATION SEQUENCING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 41 EUROPE FLUORIMMUNOASSAY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 42 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
TABLE 43 EUROPE IMMUNOHISTOCHEMICAL IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
TABLE 44 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
TABLE 45 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 138
TABLE 46 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
TABLE 47 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 139
TABLE 48 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 141
TABLE 49 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 141
TABLE 50 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
TABLE 51 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 142
TABLE 52 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
TABLE 53 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 144
TABLE 54 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 148
TABLE 55 EUROPE HOSPITALS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 150
TABLE 57 EUROPE CANCER RESEARCH CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 150
TABLE 58 EUROPE ACADEMIC INSTITUTES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 151
TABLE 59 EUROPE AMBULATORY SURGICAL CENTERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 152
TABLE 60 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
TABLE 61 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 157
TABLE 62 EUROPE DIRECT TENDER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 158
TABLE 63 EUROPE RETAIL SALES IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 159
TABLE 64 EUROPE OTHERS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 160
TABLE 65 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 167
TABLE 66 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 67 EUROPE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 68 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 69 EUROPE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 70 EUROPE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 71 EUROPE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 72 EUROPE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 73 EUROPE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 74 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 170
TABLE 75 EUROPE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 170
TABLE 76 EUROPE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 171
TABLE 77 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 171
TABLE 78 EUROPE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
TABLE 79 EUROPE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
TABLE 80 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 81 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 82 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 172
TABLE 83 EUROPE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 172
TABLE 84 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
TABLE 85 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 173
TABLE 86 EUROPE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 173
TABLE 87 EUROPE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 88 EUROPE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 89 EUROPE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
TABLE 90 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 174
TABLE 91 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
TABLE 92 EUROPE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
TABLE 93 EUROPE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
TABLE 94 EUROPE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
TABLE 95 EUROPE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
TABLE 96 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 176
TABLE 97 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 176
TABLE 98 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 99 GERMANY IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 100 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 101 GERMANY ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 102 GERMANY CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 103 GERMANY BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 104 GERMANY TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
TABLE 105 GERMANY BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
TABLE 106 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 179
TABLE 107 GERMANY STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 179
TABLE 108 GERMANY STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 179
TABLE 109 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 180
TABLE 110 GERMANY EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 111 GERMANY NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 112 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 113 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
TABLE 114 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 181
TABLE 115 GERMANY INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 181
TABLE 116 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
TABLE 117 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 181
TABLE 118 GERMANY PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 182
TABLE 119 GERMANY KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 120 GERMANY CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 121 GERMANY CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 122 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 183
TABLE 123 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 183
TABLE 124 GERMANY SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
TABLE 125 GERMANY DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
TABLE 126 GERMANY PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
TABLE 127 GERMANY RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
TABLE 128 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 185
TABLE 129 GERMANY PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 185
TABLE 130 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 186
TABLE 131 FRANCE IMAGING TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 186
TABLE 132 FRANCE MAGNETIC RESONANCE IMAGING (MRI) IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 186
TABLE 133 FRANCE ULTRASOUND IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 187
TABLE 134 FRANCE CHOLANGIOPANCREATOGRAPHY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 187
TABLE 135 FRANCE BLOOD TEST IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 187
TABLE 136 FRANCE TUMOR MARKER IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 187
TABLE 137 FRANCE BIOPSY IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 188
TABLE 138 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 188
TABLE 139 FRANCE STAGE I IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 188
TABLE 140 FRANCE STAGE II IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 188
TABLE 141 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 189
TABLE 142 FRANCE EXOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 189
TABLE 143 FRANCE NEUROENDOCRINE TUMORS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 189
TABLE 144 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 189
TABLE 145 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 190
TABLE 146 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 190
TABLE 147 FRANCE INSTRUMENT-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 190
TABLE 148 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 190
TABLE 149 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 190
TABLE 150 FRANCE PLATFORM-BASED PRODUCTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 191
TABLE 151 FRANCE KITS AND REAGENTS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 191
TABLE 152 FRANCE CA19-9 PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 191
TABLE 153 FRANCE CEA PANCREATIC CANCER TEST KITS IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 191
TABLE 154 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 192
TABLE 155 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 192
TABLE 156 FRANCE SCREENING IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 192
TABLE 157 FRANCE DIAGNOSTIC AND PREDICTIVE IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
TABLE 158 FRANCE PROGNOSTIC IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
TABLE 159 FRANCE RESEARCH IN PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
TABLE 160 FRANCE PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 194

LIST OF FIGURES

FIGURE 1 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION 49
FIGURE 2 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 52
FIGURE 3 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 53
FIGURE 4 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 54
FIGURE 5 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 54
FIGURE 6 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 55
FIGURE 7 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 57
FIGURE 8 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 59
FIGURE 9 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 60
FIGURE 10 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SEGMENTATION 64
FIGURE 11 GROWING AWARENESS OF PANCREATIC CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 65
FIGURE 12 IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030 65
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET 75
FIGURE 14 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 83
FIGURE 15 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 84
FIGURE 16 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 84
FIGURE 17 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 85
FIGURE 18 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022 97
FIGURE 19 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION) 98
FIGURE 20 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030) 98
FIGURE 21 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE 99
FIGURE 22 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2022 106
FIGURE 23 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 107
FIGURE 24 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, CAGR (2023-2030) 107
FIGURE 25 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TUMOR TYPE, LIFELINE CURVE 108
FIGURE 26 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022 114
FIGURE 27 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 115
FIGURE 28 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030) 115
FIGURE 29 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE 116
FIGURE 30 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022 125
FIGURE 31 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 126
FIGURE 32 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030) 126
FIGURE 33 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE 127
FIGURE 34 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022 135
FIGURE 35 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 136
FIGURE 36 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030) 136
FIGURE 37 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 137
FIGURE 38 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022 145
FIGURE 39 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 146
FIGURE 40 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 146
FIGURE 41 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 147
FIGURE 42 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 154
FIGURE 43 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 155
FIGURE 44 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 155
FIGURE 45 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 156
FIGURE 46 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 162
FIGURE 47 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 164
FIGURE 48 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 164
FIGURE 49 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 165
FIGURE 50 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023-2030) 165
FIGURE 51 EUROPE PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 312